力生制药(002393) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was ¥434,462,480.17, representing a 10.32% increase compared to ¥393,833,564.95 in the same period last year[9] - Net profit attributable to shareholders was ¥44,426,621.86, an increase of 8.55% from ¥40,928,973.44 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥44,552,701.33, up 8.98% from ¥40,882,368.77 in the previous year[9] - Total operating revenue for Q1 2019 was CNY 434,462,480.17, an increase of 10.3% compared to CNY 393,833,564.95 in the same period last year[37] - The company's net profit for Q1 2019 is not explicitly stated, but the increase in revenue and costs suggests a focus on growth despite rising expenses[37] - The net profit for Q1 2019 reached CNY 44,426,621.86, representing a growth of 8.73% from CNY 40,928,973.44 in Q1 2018[39] - The total profit for Q1 2019 was CNY 52,558,312.26, compared to CNY 48,419,087.02 in Q1 2018, marking an increase of 4.68%[39] - The operating profit for Q1 2019 was CNY 52,706,641.05, compared to CNY 48,372,482.35 in Q1 2018, which is an increase of 6.89%[39] - The total comprehensive income for Q1 2019 was CNY 44,426,621.86, compared to CNY 40,928,973.44 in Q1 2018, indicating an increase of 8.73%[39] Cash Flow - The net cash flow from operating activities decreased by 21.18% to ¥50,535,196.57 from ¥64,111,547.66 in the same period last year[9] - Cash received from sales increased by 30.36% to CNY 364,669,409.30 compared to the same period last year, primarily due to increased sales collections[10] - Other operating cash payments rose by 95.31% to CNY 177,496,547.09, mainly due to increased sales expenses[10] - Cash paid for dividends and interest decreased by 54.05% to CNY 339,456.25, primarily due to reduced interest expenses[10] - The company's cash inflow from operating activities was CNY 390,437,032.00, an increase from CNY 312,554,711.80 in the same period last year[43] - The net cash flow from operating activities for Q1 2019 was ¥36,416,619.29, an increase of 55.7% compared to ¥23,388,539.78 in the same period last year[46] - Total cash inflow from operating activities was ¥172,028,815.96, up from ¥146,560,637.65, reflecting a growth of 17.4%[46] - The cash flow from operating activities showed a strong performance with a net increase of ¥41,741,060.56 compared to a decrease of -¥665,706,446.58 in the previous year[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,969,144,133.39, a 1.33% increase from ¥3,917,201,547.49 at the end of the previous year[9] - Total current assets as of March 31, 2019, amounted to CNY 2,360,513,590.55, an increase from CNY 2,302,027,950.38 at the end of 2018[27] - Total assets increased to CNY 3,969,144,133.39 from CNY 3,917,201,547.49 at the end of 2018[28] - Total liabilities increased slightly to CNY 711,252,618.68 from CNY 704,846,235.46 at the end of 2018[29] - Total liabilities decreased to CNY 385,244,443.79 from CNY 403,507,866.89, showing a reduction in financial obligations[34] - The balance of other non-current assets decreased by 53.83% to CNY 9,047,147.09 compared to the beginning of the period[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,621[13] - The largest shareholder, Tianjin Jinhao Pharmaceutical Co., Ltd., held 51.36% of the shares[13] - The net assets attributable to shareholders increased by 1.42% to ¥3,257,891,514.71 from ¥3,212,355,312.03 at the end of the previous year[9] - The company's equity attributable to shareholders increased to CNY 3,257,891,514.71 from CNY 3,212,355,312.03, reflecting retained earnings and overall financial health[30] Research and Development - Research and development expenses for Q1 2019 were CNY 38,012,990.53, down from CNY 43,815,206.74 in the previous year, indicating a potential shift in investment strategy[37] - Research and development expenses for Q1 2019 were CNY 26,768,433.49, down from CNY 31,451,679.42 in Q1 2018, reflecting a decrease of 14.87%[40] Investment and Financing Activities - The company reported an investment income of CNY 2,408,205.77, significantly higher than CNY 836,259.40 in the previous year, showing an increase of 187.56%[40] - The cash outflow from investing activities was ¥3,375,804.98, significantly reduced from ¥658,917,617.30, indicating a decrease of 99.5%[46] - The net cash flow from investing activities was -¥3,372,004.98, an improvement compared to -¥658,917,617.30 in the previous year[46] - The cash flow from financing activities resulted in a net outflow of -¥789,456.25, slightly worse than -¥738,706.94 in the same quarter last year[46] Other Information - The company reported no violations regarding external guarantees during the reporting period[21] - The company has not yet audited the Q1 report, which may affect the reliability of the financial data presented[50]